Analyst Patrick Wood of Morgan Stanley maintained a Buy rating on IQVIA Holdings, with a price target of $220.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Wood has given his Buy rating due to a combination of factors that highlight IQVIA Holdings’ strong performance and potential for future growth. The company’s recent results exceeded expectations, with significant contributions from foreign exchange benefits and consistent growth in constant currency terms. Additionally, IQVIA demonstrated robust booking trends and backlog growth, indicating a positive outlook for future business.
Wood also emphasized IQVIA’s competitive advantages, such as its best-in-class clinical health network and expertise in high-demand therapeutic areas. The company’s AI-driven data solutions are expected to help it gain market share and outperform competitors. Furthermore, the positive trends in RFP flow and EBP customer segments bolster management’s confidence in their 2025 guidance, reinforcing the Overweight thesis and justifying an increased price target of $220.
In another report released yesterday, Evercore ISI also maintained a Buy rating on the stock with a $220.00 price target.